Compare US Global Jets ETF (JETS) vs Neurocrine Biosciences Inc (NBIX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
US Global Jets ETF vs Neurocrine Biosciences Inc — how do they compare? US Global Jets ETF trades at $30.55, while Neurocrine Biosciences Inc trades at $179 (market cap $17.40B). The key difference: Neurocrine Biosciences Inc is trading nearer its 52-week high, US Global Jets ETF nearer its low. Which is the better fit depends on your goals.
| JETS | NBIX | |
|---|---|---|
Sector | Sector/Thematic | Health |
52-Week High | $33.34 | $180.55 |
52-Week Low | $23.12 | $123.10 |
Market Cap | — | $17.40B |
Enterprise Value | — | $16.49B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
JETS trades at $30.58, up 0.39% with a mixed technical outlook showing bullish overall signals but bearish moving averages. The ETF faces headwinds from rising fuel costs, with U.S. airlines spending $6.66 billion on jet fuel in May 2026 (U.S. Transportation Department, 2026-07-07), though lower oil prices recently provided some relief. Recent news highlights volatility from Middle East conflicts and competitive pressure from defense-focused ETFs.
Outlook remains cautious due to cyclical exposure and fuel cost sensitivity. Investment opportunity hinges on sustained oil price declines, but risks include geopolitical tensions and airline profit pressures. Analyst sentiment is neutral with a Hold rating, emphasizing the ETF's concentration in industrials and high volatility.
Neurocrine Biosciences (NBIX) trades at $173.00, up 1.24% today, with strong technical momentum and bullish moving averages. The company demonstrates robust fundamentals with Q1 2026 EPS of $1.94 beating expectations by 59%, revenue growth to $3.1B in 2026, and net income margin expanding to 21.55%. Recent news highlights executive appointments and positive clinical trial updates for crinecerfont, supporting growth prospects.
Outlook remains positive with 86% analyst buy ratings and a $196.08 consensus price target implying 13% upside. Key risks include execution of pipeline developments and integration of acquisitions. The stock's valuation at P/E 26.62 appears reasonable given earnings growth trajectory and strong profitability metrics.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About US Global Jets ETF
JETS provides targeted exposure to the global airline industry, including commercial airlines, aircraft manufacturers, and airport operators. It focuses on major U.S. and international carriers like Delta, United, and American Airlines.
Read more on JETS →About Neurocrine Biosciences Inc
Neurocrine Biosciences, Inc. is a biopharmaceutical company focused on discovering, developing, and commercializing innovative treatments for neurological, endocrine, and psychiatric disorders. The company's portfolio targets conditions such as tardive dyskinesia, endometriosis, and Parkinson's disease. NBIX leverages its expertise in neurobiology and small-molecule drug development to address diseases with significant unmet medical needs.
Read more on NBIX →
